Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
SH Cho, LC Park, JH Ji, S Park, DW Hwang… - Cancer chemotherapy …, 2012 - Springer
Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
Z Song, Y Yu, Z Chen, S Lu - Chinese Medical Journal, 2011 - mednexus.org
Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …
Gefitinib therapy for non-small cell lung cancer
A Birnbaum, N Ready - Current treatment options in oncology, 2005 - Springer
Opinion statement Gefitinib is a small molecule that specifically inhibits the tyrosine kinase
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer …
Background Epidermal growth factor receptor (EGFR) mutations are associated with
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer: current knowledge and future directions
W Pao, VA Miller - Journal of Clinical Oncology, 2005 - ascopubs.org
Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …